Recent advances in plasma biomarkers (mainly ptau217) are enabling earlier, less invasive, and more cost-effective detection, with several assays achieving >90% accuracy and receiving regulatory clearance for clinical use as triage or adjunct tools. In parallel, digital cognitive testing platforms are improving the sensitivity and scalability of functional assessment, while passive digital biomarkers—derived from speech, behavior, and device usage patterns—are emerging as continuous, real-world indicators of cognitive decline. Together, these modalities are increasingly positioned as front-line screening tools, with positive cases confirmed via PET or CSF, reflecting a tiered, multi-modal diagnostic workflow. Lampros is speaking at the ADDF/ADDI panel at ADPD 2026 in Copenhagen on the commercialization of Alzheimer’s diagnostic technologies.
